Get to know Ari Tolonen – the consultant behind Druglike Consulting, with a long-standing background in ADME/DMPK research and pharma industry collaboration.
Ari has over 20 years history in preclinical ADME/DMPK research and in use of LC/MS based analytical technology, supporting pharmaceutical industry from the CRO point of view. In 2011, he founded preclinical ADME-Tox CRO Admescope, and worked there until 2021 as a CEO and until 2024 as a CSO. Over the years he has gathered a wide experience in optimizing and developing ADME/DMPK assays and workflows, in designing strategies and cascades for selection of the most promising compounds, and in working with multiple drug modalities from small molecules to peptides, ASOs, mAbs, and ADCs, with a key focus in biotransformations & metabolic reaction phenotyping.
He has worked with hundreds of biotechs and pharma companies in > 30 countries, published > 70 peer reviewed original and review articles in the field of ADME/DMPK and bioanalytical chemistry, and supervised 14 academic MSc and PhD examinations.
"*" indicates required fields
